Mining for functionality

Conventional antibody discovery platforms generate a small number of candidates that block a target, and even fewer that can alter the function of target cells. HiFiBiO S.A.S. has a platform that improves the odds of finding a viable therapeutic by rapidly producing large, genetically diverse sets of functional antibodies.

Standard platforms like phage display and hybridoma-based systems select antibodies based primarily on their ability to bind the target antigen. "So if you're looking for antibodies that make a functional change in a target cell, these platforms alone aren't sufficient," Chief Commercial Officer Colin Brenan told BioCentury...